364 related articles for article (PubMed ID: 26214590)
1. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.
Krauthammer M; Kong Y; Bacchiocchi A; Evans P; Pornputtapong N; Wu C; McCusker JP; Ma S; Cheng E; Straub R; Serin M; Bosenberg M; Ariyan S; Narayan D; Sznol M; Kluger HM; Mane S; Schlessinger J; Lifton RP; Halaban R
Nat Genet; 2015 Sep; 47(9):996-1002. PubMed ID: 26214590
[TBL] [Abstract][Full Text] [Related]
2. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
[TBL] [Abstract][Full Text] [Related]
3. The NF1 gene in tumor syndromes and melanoma.
Kiuru M; Busam KJ
Lab Invest; 2017 Feb; 97(2):146-157. PubMed ID: 28067895
[TBL] [Abstract][Full Text] [Related]
4. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
[TBL] [Abstract][Full Text] [Related]
5. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.
Cirenajwis H; Lauss M; Ekedahl H; Törngren T; Kvist A; Saal LH; Olsson H; Staaf J; Carneiro A; Ingvar C; Harbst K; Hayward NK; Jönsson G
Mol Oncol; 2017 Apr; 11(4):438-451. PubMed ID: 28267273
[TBL] [Abstract][Full Text] [Related]
6. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
[TBL] [Abstract][Full Text] [Related]
7. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
Hintzsche JD; Gorden NT; Amato CM; Kim J; Wuensch KE; Robinson SE; Applegate AJ; Couts KL; Medina TM; Wells KR; Wisell JA; McCarter MD; Box NF; Shellman YG; Gonzalez RC; Lewis KD; Tentler JJ; Tan AC; Robinson WA
Melanoma Res; 2017 Jun; 27(3):189-199. PubMed ID: 28296713
[TBL] [Abstract][Full Text] [Related]
8. NF1 mutations in conjunctival melanoma.
Scholz SL; Cosgarea I; Süßkind D; Murali R; Möller I; Reis H; Leonardelli S; Schilling B; Schimming T; Hadaschik E; Franklin C; Paschen A; Sucker A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Br J Cancer; 2018 May; 118(9):1243-1247. PubMed ID: 29559732
[TBL] [Abstract][Full Text] [Related]
9. NF1 Mutations Prevalent but Not Clinically Relevant.
Cancer Discov; 2015 Oct; 5(10):OF1. PubMed ID: 26283687
[TBL] [Abstract][Full Text] [Related]
10. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
[TBL] [Abstract][Full Text] [Related]
11. Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver?
Kadokura A; Frydenlund N; Leone DA; Yang S; Hoang MP; Deng A; Hernandez-Perez M; Biswas A; Singh R; Yaar R; Mahalingam M
Hum Pathol; 2016 Jul; 53():82-90. PubMed ID: 26980030
[TBL] [Abstract][Full Text] [Related]
12. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
13. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Krauthammer M; Kong Y; Ha BH; Evans P; Bacchiocchi A; McCusker JP; Cheng E; Davis MJ; Goh G; Choi M; Ariyan S; Narayan D; Dutton-Regester K; Capatana A; Holman EC; Bosenberg M; Sznol M; Kluger HM; Brash DE; Stern DF; Materin MA; Lo RS; Mane S; Ma S; Kidd KK; Hayward NK; Lifton RP; Schlessinger J; Boggon TJ; Halaban R
Nat Genet; 2012 Sep; 44(9):1006-14. PubMed ID: 22842228
[TBL] [Abstract][Full Text] [Related]
14. Intragenic NF1 deletions in sinonasal mucosal malignant melanoma.
Riobello C; Casanueva Muruais R; Suárez-Fernández L; García-Marín R; Cabal VN; Blanco-Lorenzo V; Franchi A; Laco J; López F; Llorente JL; Hermsen MA
Pigment Cell Melanoma Res; 2022 Jan; 35(1):88-96. PubMed ID: 34547192
[TBL] [Abstract][Full Text] [Related]
15. Recurrent inactivating RASA2 mutations in melanoma.
Arafeh R; Qutob N; Emmanuel R; Keren-Paz A; Madore J; Elkahloun A; Wilmott JS; Gartner JJ; Di Pizio A; Winograd-Katz S; Sindiri S; Rotkopf R; Dutton-Regester K; Johansson P; Pritchard AL; Waddell N; Hill VK; Lin JC; Hevroni Y; Rosenberg SA; Khan J; Ben-Dor S; Niv MY; Ulitsky I; Mann GJ; Scolyer RA; Hayward NK; Samuels Y
Nat Genet; 2015 Dec; 47(12):1408-10. PubMed ID: 26502337
[TBL] [Abstract][Full Text] [Related]
16. The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma.
Guhan SM; Shaughnessy M; Rajadurai A; Taylor M; Kumar R; Ji Z; Rashid S; Flaherty K; Tsao H
J Invest Dermatol; 2021 Aug; 141(8):2018-2027.e4. PubMed ID: 33745909
[TBL] [Abstract][Full Text] [Related]
17. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
Whittaker SR; Theurillat JP; Van Allen E; Wagle N; Hsiao J; Cowley GS; Schadendorf D; Root DE; Garraway LA
Cancer Discov; 2013 Mar; 3(3):350-62. PubMed ID: 23288408
[TBL] [Abstract][Full Text] [Related]
18. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
Rajkumar S; Berry D; Heney KA; Strong C; Ramsay L; Lajoie M; Alkallas R; Nguyen TT; Thomson C; Ahanfeshar-Adams M; Dankner M; Petrella T; Rose AAN; Siegel PM; Watson IR
Cell Rep; 2022 Apr; 39(1):110634. PubMed ID: 35385748
[TBL] [Abstract][Full Text] [Related]
19. RASopathy Gene Mutations in Melanoma.
Halaban R; Krauthammer M
J Invest Dermatol; 2016 Sep; 136(9):1755-1759. PubMed ID: 27236105
[TBL] [Abstract][Full Text] [Related]
20. Integrated molecular drivers coordinate biological and clinical states in melanoma.
Conway JR; Dietlein F; Taylor-Weiner A; AlDubayan S; Vokes N; Keenan T; Reardon B; He MX; Margolis CA; Weirather JL; Haq R; Schilling B; Stephen Hodi F; Schadendorf D; Liu D; Van Allen EM
Nat Genet; 2020 Dec; 52(12):1373-1383. PubMed ID: 33230298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
